Aligning Clinical Evidence With Managed Care Decision-Making in the Evolving Myelofibrosis Treatment Landscape

Program Description

Myelofibrosis, a chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, splenomegaly, cytopenias, and debilitating constitutional symptoms, presents substantial challenges in both clinical management and health system resource utilization. Despite the availability of Janus kinase inhibitors (JAKis), disease progression, anemia, and thrombocytopenia remain persistent barriers to optimal outcomes. In recent years, there has been a push for individualized treatment sequencing strategies and the integration of emerging disease-modifying agents. The treatment landscape has expanded beyond JAKi monotherapy to include ruxolitinib-based combinations and agents with novel mechanisms of action and the potential to not only reduce spleen size and improve symptoms but also modify the disease trajectory. Oncology pharmacists in managed care roles must be ready to interpret emerging clinical trial data and assess how these novel therapies can be integrated into practice. This program presents the latest evidence on guideline-directed therapy selection, molecular risk stratification, and real-world data to inform formulary and coverage decisions. Participants will explore strategies to optimize transitions between therapies, manage treatment-related anemia, and address the economic and quality-of-life burden associated with myelofibrosis. Expert speakers will break down clinical trial evidence, current guidelines, and value-based care principles, equipping pharmacists to support patient-centered outcomes and ensure the appropriate, cost-effective use of novel and established therapies in myelofibrosis.

Target audience: Managed Care Pharmacist, Oncology Pharmacist
Type of activity: Application
Release date: April 30, 2026
Expiration date: April 30, 2027
Learner level: Foundational, Intermediate
Time to complete activity: 1.5 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Analyze the latest clinical evidence, guideline updates, and emerging therapeutic strategies in myelofibrosis to inform evidence-based formulary decisions and ensure the appropriate use of available drug therapies.
• Apply best practices for sequencing and transitioning patients with myelofibrosis to subsequent therapies following progression or intolerance, with attention to safety, efficacy, and supportive care considerations.
• Examine the clinical and economic burden of myelofibrosis and strategies to optimize patient outcomes and value-based care through integration of novel therapies and real-world evidence.

Accreditation

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-26-089-H01-P. The activity is available for CE credit through April 30, 2027.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

James A. Davis, PharmD, BCOP, has the following relevant financial relationships with ineligible companies to disclose: Speaker: GSK, Janssen; Consultant: BMS, GSK, Janssen

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, has the following relevant financial relationships with ineligible companies to disclose: Consultant: BMS, Pfizer, Sanofi

Pharmacy Times Continuing Education™ Planning Staff: Jim Palatine, RPh, MBA; Daphne Davis, PharmD, BCOP; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta have no financial relationships with ineligible companies to disclose.

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms